SNORD113-1: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD113-1

NCBI ID: G767561

SNORD113-1

Other Name(s): Small nucleolar RNA, C/D box 113-1 | small nucleolar RNA, C/D box 113-1 | 14q(I-1)

SNORD113-1: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known snRNAs is SNORD113-1, which is a 22-nt RNA molecule located within the C/D box region on chromosome 17. Despite its small size, SNORD113-1 has been shown to play important roles in various cellular processes, including DNA replication, gene expression, and cellular signaling pathways.

The discovery and characterization of SNORD113-1 has important implications for our understanding of small RNA biology and the potential for this molecule to serve as a drug target or biomarker. In this article, we will discuss the biology of SNORD113-1, its potential functions as a drug target, and its potential as a biomarker for various diseases.

SNORD113-1 Biology and Functions

SNORD113-1 is a member of the small nucleolar RNA (snRNA) family, which includes a variety of non-coding RNAs that play critical roles in regulating gene expression in eukaryotic cells. The snRNA family is characterized by the presence of a stem-loop and a rich array of post-transcriptional modifications, such as poly(A) tail and various modifications in the 5' and 3' ends of the RNA molecule.

Studies have shown that SNORD113-1 plays important roles in various cellular processes, including DNA replication, gene expression, and cellular signaling pathways. For example, SNORD113-1 has been shown to be involved in the regulation of DNA replication, specifically in the initiation of DNA replication in the first strand. Additionally, SNORD113-1 has been shown to play a role in regulating gene expression by binding to specific DNA sequences and affecting the accessibility of these sequences for transcription factors.

In addition to its role in regulating gene expression, SNORD113-1 has also been shown to play important roles in cellular signaling pathways. For example, studies have shown that SNORD113-1 can interact with the protein Scl/TAL1, which is involved in the regulation of cellular signaling pathways. This interaction between SNORD113-1 and Scl/TAL1 suggests that SNORD113-1 may be a potential drug target or biomarker associated with cellular signaling pathways.

Potential Functions as a Drug Target

The potential function of SNORD113-1 as a drug target is an exciting area of 鈥嬧?媟esearch, as the regulation of small RNA biology has been implicated in the development and progression of various diseases. SNORD113-1 has been shown to play important roles in the regulation of cellular signaling pathways, including the regulation of cell growth, apoptosis, and DNA replication. As such, SNORD113-1 may be a potential drug target for diseases that are characterized by the disruption of these signaling pathways, such as cancer, neurodegenerative diseases, and genetic disorders.

One potential approach to targeting SNORD113-1 as a drug is to use small molecule inhibitors that specifically interact with the SNORD113-1 protein. These inhibitors could be used to reduce the levels of SNORD113-1 in cells and disrupt its functions, leading to the inhibition of cellular signaling pathways and the inhibition of the development and progression of disease.

Potential Use as a Biomarker

SNORD113-1 has also been shown to serve as a potential biomarker for various diseases. The regulation of small RNA biology has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and genetic disorders. As such, the measurement of SNORD113-1 levels in cells or fluids, such as blood or urine, may be a potential

Protein Name: Small Nucleolar RNA, C/D Box 113-1

The "SNORD113-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets